

JACOBSON PHARMA CORPORATION LIMITED

Incorporated under the laws of the Cayman Islands with limited liability Stock Code : 2633



Interim Report 2018

CONTENTS

2 Corporate Information

3 Financial Highlights

4 Letter to Shareholders

6 Corporate Vision and Mission

7 Corporate Profile

8

Management Discussion and Analysis

19

Other Information

27 Review Report to the Board of Directors

28 Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income

29 Unaudited Consolidated Statement of Financial Position

30 Unaudited Consolidated Statement of Changes in Equity

31 Unaudited Condensed Consolidated Cash Flow Statement

32 Notes to the Unaudited Interim Financial Report

47 Glossary

CORPORATE INFORMATION

BOARD OF DIRECTORS Executive Directors

Mr. Sum Kwong Yip, Derek ^(Chairman and Chief Executive Officer) Mr. Yim Chun Leung Ms. Pun Yue Wai

Non-executive Director Professor Lam Sing Kwong, Simon

Independent Non-executive Directors Dr. Lam Kwing Tong, Alan Mr. Young Chun Man, Kenneth

Mr. Young Chun Man, Kenneth Professor Wong Chi Kei, lan

AUDIT COMMITTEE

Mr. Young Chun Man, Kenneth (Chairman) Dr. Lam Kwing Tong, Alan Professor Wong Chi Kei, Ian

REMUNERATION COMMITTEE

Dr. Lam Kwing Tong, Alan (Chairman) Mr. Young Chun Man, Kenneth Ms. Pun Yue Wai

NOMINATION COMMITTEE

Professor Wong Chi Kei, Ian (Chairman) Dr. Lam Kwing Tong, Alan Mr. Young Chun Man, Kenneth Mr. Yim Chun Leung

AUTHORISED REPRESENTATIVES Mr. Yim Chun Leung Ms. Wu Lai King

COMPANY SECRETARY Ms. Wu Lai King

REGISTERED OFFICE

Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands

CORPORATE HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 2313-18, 23/F Tower 1, Millennium City 1 388 Kwun Tong Road Kwun Tong, Kowloon Hong Kong

PRINCIPAL SHARE REGISTRAR

AND TRANSFER OFFICE Conyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR

Tricor Investor Services Limited Level 22, Hopewell Centre 183 Queen's Road East Hong Kong

AUDITOR KPMG

KPMG

PRINCIPAL BANKERS

(in alphabetical order) China Construction Bank (Asia) Corporation Ltd. Standard Chartered Bank The Hongkong and Shanghai Banking Corporation Limited

PUBLIC RELATIONS CONSULTANT Strategic Public Relations Group

STOCK CODE 2633

COMPANY WEBSITE www.jacobsonpharma.com

FINANCIAL HIGHLIGHTS

	Six months ended 30 September 2018	Six months ended 30 September 2017	Change
	HK\$'000	HK\$'000	
Revenue			
- Generic Drugs	595,227	542,225	+9.8%
- Proprietary Medicines	110,743	121,183	-8.6%
– Wholesale and Retail	110,290	79,624	+38.5%
Total	816,260	743,032	+9.9%
Gross profit	318,694	278,904	+14.3%
Gross profit margin (%)	39.0%	37.5%	
Profit attributable to shareholders of the Company	97,531	80,329	+21.4%
Profit margin attributable to shareholders of the Company (%)	11.9%	10.8%	
Adjusted EBITDA (1)	211,516	166,243	+27.2%
Adjusted EBITDA margin [%] (2)	25.9%	22.4%	
Return on equity (%) (3)	9.1%	9.2%	
	As at		
	30 September 2018	As at 31 March 2018	Change
	HK\$'000	HK\$'000	
Total assets	4,116,280	3,611,155	+14.0%
Total liabilities	1,555,807	1,603,180	-3.0%

 Adjusted EBITDA is calculated based on adjusted earnings before interest, taxes, depreciation and amortisation, where "interest" is regarded as including interest income and interest expenses and "depreciation and amortisation" is regarded as including impairment losses on non-current assets. To arrive at adjusted EBITDA the Group's earnings are further adjusted for non-recurring items not attributable to the operations of individual segments.

2,560,473

2,007,975

(2) Adjusted EBITDA margin is calculated based on adjusted EBITDA divided by revenue and multiplied by 100%.

Total equity

(3) Return on equity is calculated based on annualised profit for the period divided by the arithmetic mean of the opening and closing balances of total equity in the relevant period and multiplied by 100%.



+27.5%

LETTER TO SHAREHOLDERS

Dear Shareholders,

Just around two months ago we celebrated the 20th anniversary of Jacobson with our long-serving management staff. Whilst we spent the evening reminiscing the past, the event was more focused on the future. We talked a lot about how the scientific and technological advances would impact upon the market dynamics of the healthcare industry, and how one should seize the opportunities and take the lead in this burgeoning field of technologies.

No doubt we are in a challenging and fast-changing environment. With the fundamental advances in science and technology, we expect to see some material shift in the way the industry operates, the way we use data and analytics to develop new formulations and genomic-based medicines, and the way we interact with patients, consumers and healthcare professionals. As life-threatening and chronic diseases such as cancer, auto-immune disorders, cardiovascular and diabetes are getting prevalent, the demand for healthcare services and innovative medicines is more intense than ever.

The good news is that this market is full of opportunities, first and foremost with the breakthroughs and advances in science, perhaps most notably in genomics and also some exciting new frontiers such as clinical diagnostics and biologics. As we strengthen the Company to forge a platform for future success, we must make sure that we drive the performance through creating sustainable strategic values upon our core businesses. In this regard, R&D output and in-licensing capabilities are deemed as the growth drivers over the next few years, and these attributes would have a profound impact on the strategic development of the Company. So it is important that we remain agile and have the foresight to seize the opportunities evolved from the scientific advances.

Prospect

For the past twenty years, we have remained dedicated to building a vision-driven company, a company that promotes a performance culture, fosters positive values and cherishes teamwork and people. Our vision has been clear and consistent. We aim to make Jacobson an eminent player to be reckoned with in the delivery of generic drugs and proprietary medicines to the healthcare professionals and the public in Asia. Our mission matters i.e. to improve the access of cost-effective medicines and healthcare services to those in need. This mission has been underpinned by our quest for innovation and new ideas on both products and services.

Whilst we embrace the second half of the year, I would like to take this opportunity to shed some light on our interim results. Businesswise, we have performed well delivering a solid growth of +9.9% on total revenue and a staggering jump of +40.7% on profits from operations, primarily attributable to a steady and yet progressive growth in the generic drug business along with a realisation of operating leverage across our production plants. Sales growth and cost-saving measures have seen cash-flow and margin improvements for the generic drug business over the last 12 months. The supply position in our new production lines is stabilising, providing a solid platform for us to reap further growth in the second half of the year. Year-to-date, we have launched a total of 15 new products including formulations like Quetiapine Extended Released Tablets, Diltiazem Controlled Release Tablets, Celecoxib Capsules, Irbesartan Tablets and Levocetirizine Tablet. In the R&D pipelines, we are making good progress on over 60 projects covering various therapeutic categories, indications and dosage forms.

We remain committed to achieving the full year performance. Our recent progress on expanding our product portfolio as well as extending our geographical reach in Asia demonstrates our capabilities to execute on our growth strategies. We have secured the in-licensing agreements on three medical nutrition lines respectively from Norway, France and Italy covering Greater China as well as certain strategic markets in Asia. On the pharma front, we have also licensed in a blockbuster drug, Tenofovir Tablet, to tap the public hospital and prescription market segments in Hong Kong and Macau. A new representative office has been opened in Taipei since September and we aim to set up our presence in Singapore and Guangzhou towards Q1 2019. These milestones are the culmination of our year-long investment in people network, business development and research disciplines.

Strategic Growth Framework

Alongside our three-year growth plan, we are setting out the strategic framework which comprises four key priorities:

- a. The priority has always been our generic drug business. We are very focused on maximising the commercial opportunities for our recent and near-term product launches. We aim to increase the market shares of our businesses in markets we operate via organic growth and expansion of targeted portfolio through in-licensing or products developed in-house.
- b. Adopt the partnership-driven model and execute on complimentary capabilities for making entry into new markets or business segments. Forge strategic alliances or join forces with local partners when the market dynamics favours such an option.
- c. Strategies based on merger & acquisition will be pursued in a sensible manner. Aim for products or franchises with the right strategic fit that would create long term strategic values to our existing business portfolio.
- d. Establish a regional operational platform in Greater China and ASEAN, strengthen our commercial and regulatory capabilities in the process and aim to make Jacobson a preferred partner of choice to work with for other multi-national companies. With this, we could leverage our strategic position, expand into new markets and diversify our revenue stream by offering a portfolio of generic drugs, specialty medicines and proprietary products.

Appreciation

In a nutshell, we are setting out a clear roadmap forward over the next three years. Our aim is to have all of our businesses deliver performances with clear pathways for creating sustainable growth and healthy returns to our shareholders. With this, I would like to thank our colleagues and directors of the board for giving us their trust and support along the journey, and to our Shareholders for your confidence in Jacobson.

Sincerely yours

Sum Kwong Yip Derek Chairman and CEO JACOBSON PHARMA CORPORATION LIMITED

Hong Kong, 21 November 2018



CORPORATE VISION AND MISSION



OUR VISION

At Jacobson, we aspire to be a leading company in generic drugs and proprietary medicines in Asia Pacific and beyond.

OUR MISSION

We strive to create sustainable values that meet current and future customer needs through carefully-orchestrated investment in R&D.

We enhance the communities in which we operate.

We build shareholder values in all we do.

OUR CULTURE

Three core components, i.e. Challenge, Connect, Commit, unite our corporate culture and values that define how we act and what we do:

Challenge

We proactively venture into uncharted turf for exploring opportunities. We go the extra-mile for attaining excellence via innovative solutions.

Connect

We work cohesively as one company one team to create and share best practices. We connect local knowledge with global resources.

Commit

We deliver on what we promise. We do not compromise on quality and integrity.

CORPORATE PROFILE

The Group is a leading generic drug company in Hong Kong representing about 30% share of the total generic drug sales of the market. The Group has been a major provider of generic drugs to the Public Sector in Hong Kong, accounting for approximately 70% of their annual purchase of generic drugs. It is also a leading provider of generic drugs in Hong Kong in the Private Sector with about 20% share in revenue term. ^{(Note/} The Group achieved its pre-eminent market position as a result of its leadership in a number of therapeutic categories, as well as in distribution, product development and drug manufacturing.

The Group's proprietary medicines portfolio currently comprises brands including Po Chai Pills (保濟丸), Ho Chai Kung Tji Thung San (何濟公止痛 退熱散), Tong Tai Chung Woodlok Oil (唐太宗活絡油), Flying Eagle Woodlok Oil (飛鷹活絡油), Saplingtan (十靈丹), Shiling Oil (十靈油) and Col-gan Tablet (傷風克). All these brands carry a high recognition amongst the consumers and enjoy a strong market position thus creating sustainable synergies for marketing and distribution resources under the management of the Group.

COMPETITIVE STRENGTHS

• LEADERSHIP IN A DIVERSE RANGE OF ESSENTIAL AND SPECIALTY DRUGS IN HONG KONG

Over a long and successful track record, we have built a comprehensive product portfolio, including respiratory, cardiovascular, central nervous system, gastrointestinal, scar treatment and oral anti-diabetics, cementing our position as the leader in a number of large and fast-growing therapeutic categories in the Hong Kong pharmaceutical market. We continually expand our portfolio to reinforce our leadership position with a strategic focus on specialty drugs and biosimilars to tap the fast growing market segments.

HIGHLY RECOGNISED AND WIDELY CARRIED PROPRIETARY MEDICINES

We own, manufacture and distribute a portfolio of leading proprietary medicines. Based on our deep familiarity with the market, strong technical support and disciplined brand management, we have been able to grow revenues, enhance manufacturing capabilities and increase local and regional market coverage for the proprietary medicine brands we have acquired.

LEADING RESEARCH AND DEVELOPMENT CAPABILITIES THAT CAN DEVELOP PREMIUM GENERIC DRUGS AND HEALTHCARE SOLUTIONS TO FULFILL UNMET DEMANDS

We are the leading pharmaceutical research and development company in Hong Kong among generic drug manufacturers in terms of number of new drugs registered in the past few years. We have been able to identify products with good potential based on our strong relationships with customers and deep market insight. We actively explore collaborations with local and overseas R&D institutions and companies on the development of innovative technologies for pharmaceutical manufacturing and diagnostic tools.

WELL-ESTABLISHED SALES AND DISTRIBUTION NETWORK WITH EXTENSIVE MARKET COVERAGE

We have extensive local market penetration, covering substantially all of the Public and Private Sector institutions and registered pharmacies, as well as over 1,000 doctors in private practice. Our deep industry knowledge, extensive sales network and close interactions with market participants enable us to gather significant feedback, relevant market intelligence and data on industry trends for further strengthening our product development strategies and identifying business opportunities. We are also committed to the strategy of expanding our regional presence into strategically selected markets in Asia Pacific.

Note: source: Frost & Sullivan (Beijing) Inc, Shanghai Branch Co.



MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

GENERIC DRUGS

Sustained Growth for Both Private and Public Sectors

During the first six months period ended 30 September 2018, the Group registered a steady year-on-year growth of 9.8% for its generic drug business, posting approximately HK\$595.3 million in sales revenue.

The sustained growth was mainly contributed by an expanded product portfolio and a broadened customer base along with an enhanced production capacity delivering a steady stock supply in both Private and Public Sectors, posting a growth of 10.4% to HK\$395.2 million and 8.7% to HK\$200.1 million respectively during the reporting period.

The growth of sub-sector markets such as those for cardiovascular and central nervous system treatments has been strong, attributable to the increasing prevalence of chronic diseases and the ageing population. In the Public Sector, Losartan Tablet (angiotensin II antagonists) and Amlodipine Tablet (calcium antagonists) within the Group's cardiovascular product series, for instances, recorded a sales growth of 33.4% and 19.4% respectively as compared with the same period of 2017. Among the Group's central nervous system product series, the hypnotics class recorded a growth of 71.0% with the award of a new tender for Zolpidem Tablet, whilst the antipsychotics class recorded a 42.6% growth with new tenders secured for Amisulpride Tablet and Pericyazine Tablet. In addition, newly secured tenders for Gliclazide Tablet also contributed to a growth of 41.0% for the Group's oral anti-diabetics sales during the reporting period.

For the Private Sector, sales of the Group's angiotensin II antagonists products, including the newly launched product Irbesartan Tablet, also recorded a strong growth of 76.8%, alongside a 29.5% growth in sales of lipid-lowering drugs. In addition, the hypnotics class products within the central nervous system treatments posted a notable growth of 45.2% as compared with the same period of 2017. New products launched during the reporting period in the Private Sector also included Quetiapine Extended Released Tablet, Celecoxib Capsule and Levocetirizine Tablet.

With the elderly population aged above 70 reaching 830,000 in Hong Kong by 2019, the surging demand in medical care and rising healthcare expenditure will continue to be a growing challenge to the public healthcare system. The Group believes the adoption of generic drugs substitution policy by the health authorities as a cost containment measure would continue to positively impact the growth prospects of the local generic drugs market. The government's increased spending on subsidy programmes, such as the Elderly Health Care Voucher Scheme and the General Outpatient Clinic Public Private Partnership Programme aimed at alleviating the strain in the public healthcare system, will divert part of the increasing healthcare demand to the Private Sector for which the Group is well positioned to serve as a leading provider of generic drugs in the sector.

Increased Production Output and Efficiency

All of the Group's manufacturing units operated effectively during the reporting period with production outputs totalling 1,408 million tablets and capsules, 170 tonnes of cream products and 1,281 thousand litres of oral liquid. The solid and semi-solid dosage outputs recorded a respective growth of 5.0% and 26.4% as compared with the same period of last year.

Equipped with machinery for high throughput capability, the new PIC/S GMP accredited manufacturing plant at Synco (H.K.) Limited further ramped up its solid dosage and liquid output by 39.2% and 191.5% respectively over the same period of last year, amounting to 356.4 million tablets and capsules and 154.4 thousand litres of oral liquid.

The newly acquired business units continued to contribute to the enhancement of the Group's production capability and capacity. Medipharma Limited, for instance, grew by 119.6% and 14.6% respectively in semi-solid and oral liquid outputs, whilst Karen Pharmaceutical Company Limited reported a 23.2% growth in solid dosage output compared with the same period of last year.

The continued enhancement of the production output and efficiency of the Group was driven by the successful integration and streamlining of our newly acquired manufacturing facilities to cater for the increasing market demand.

Business Development to Strengthen Portfolio and Drive Expansion

The Group has been taking a strong market position in a number of the high performing therapeutic categories. To supplement its R&D pipeline and strengthen its leadership in specific categories, the Group has actively collaborated with pharmaceutical suppliers in Spain, Korea, and Taiwan for the introduction of new and specialized products such as Tenofovir Tablet, Esomeprazole Tablets, Duloxetine Capsules and Oseltamivir Capsule to broaden its portfolio. The Group is aiming to secure more products including sterile injections, oncology products, combination drugs and specialty drugs, as well as biosimilars, thereby further strengthening its position to tap health care demand of the local and regional markets in Asia. Currently, 46 such products have been secured and are undergoing different stages of new product registration in Hong Kong.

The Group has also entered into in-licensing agreements with reputable manufacturers in Europe, namely Smartfish from Norway, Difass from Italy and Indigo of France, for three lines of medical nutrition products to target the high potential functional food and Food for Special Medical Purpose (FSMP) market segments, which will be launched in Greater China and selected Asian countries starting in 2019 and onwards.

In line with the Group's vision and development, it has continued to extend its footprints in certain strategic markets in Asia with plans to set up new offices in China, Taiwan, Singapore, Korea, and Cambodia. By leveraging its regional platform, the Group is well-poised to collaborate strategically with reputable partners globally through licensing, technology transfer or representation of finished branded products so as to expand its market presence in the Asia Pacific region.

PROPRIETARY MEDICINES

Sustained Efforts in Building Strong Brands

During the reporting period, the total revenue from the proprietary medicines segment of the Group amounted to HK\$110.7 million, representing a 8.7% drop over the same period of last year as the pressure on sales from the unfavourable market sentiments was reflected in the reporting period when compared to the notable performance of last year.

Despite the considerable slowdown of the retail market in Hong Kong, Po Chai Pills (保濟丸) continued to strengthen its leadership position in the gastro-intestinal Chinese medicine category with persistent and assiduous efforts in marketing and brand building, posting an organic growth of 7.0% in sales revenue in local market as compared with the same period of last year.

Along with the objective to broaden the brand's appeal to younger consumers, a new creative advertising campaign of Po Chai Pills was launched recently under the theme "Fast Relief of 5 Major Gastrointestinal Problems" inviting Jim Yan Chi Hong, a well-known radio DJ and artist with a humorous appeal, to play the role of multiple comical characters in the production. This highly creative approach proved to be a hit in its launch with the high viewership rate and positive comments from the online and social media platforms.

In spite of the strong US currency and unfavourable economic conditions in Asian countries, overseas sales of Po Chai Pills in markets like Singapore, Malaysia and Thailand also registered an encouraging growth of 34.8% as compared with the same period of last year, successfully driven by the Group's ongoing brand advertising and promotion effort.

The business of medicated oils of the Group also showed remarkable growth in 2018. Sales revenue of Flying Eagle Woodlok Oil (飛鷹活絡油) posted a 91.9% increase compared with the same period of last year. Sales revenue of Shiling Oil (十靈油) rose 67.6% during the reporting period, as a result of strengthened distribution management and advertising drive. Enhanced marketing efforts and resources have been allocated for boosting the brand image of Shiling Oil, with new product development under Shiling Oil in the pipeline.



Disciplined Approach with Focus on Specialized Formulations

With a disciplined approach and effective management, the Group's R&D continued to make good progress in its product development pipeline. A total of 11 products, including Aripiprazole Tablet, Finasteride Tablet, Etoricoxib Tablet, Lamivudine and Abacavir Tablet, Diltiazem HCl Controlled Release Tablet, for instance, were successfully registered during the reporting period and are ready for launch and supply in Hong Kong. Eight other new products have completed the development process and testing, and applications for approval have been submitted to the Department of Health.

As at the end of September 2018, there are 102 products in the Group's pipeline, 38 of which have been approved for registration, 8 have been submitted for registration, and 32 items have completed development and are currently under stability evaluation process. Within the reporting period, seven new items were added to the Group's pipeline.

R&D COLLABORATION

Technology Transfer of an Innovative Non-invasive Technology in Prostate Cancer Screening

During the reporting period, we have made good progress in finalising the transfer of intellectual property right and licensing agreement with the target company in the collaborative development of an innovative, non-invasive, accurate diagnostic test of prostate cancer. Plans and timelines have been worked out for the establishment of accreditation facilities, multi-center clinical trials, regulatory registration, commercialisation plan in Hong Kong and other major markets, which are being carried out by designated task forces.

This innovative home-based and non-invasive screening device for Prostate Cancer will be targeted for the global market with commercial rollout starting in Hong Kong and Macau from 2019 onwards. The technology can provide a fast and convenient option to verify the results of the "gold standard" test on prostate cancer screening, i.e., blood prostate-specific antigen (PSA) level, with the benefits of better patient experience and the minimisation of possibly unnecessary prostate biopsy procedures. A multi-center clinical trial is being undertaken for the verification and comparative study of this innovative technology against the widely recognised "gold standard" test.

Collaboration Project with Hong Kong Institute of Biotechnology (HKIB)

During the reporting period, steady progress has been made to scale up the project to production site for the actual manufacturing process in the second phase studies.

The collaboration project with HKIB for "Real-time Monitoring and End Point Determination of Pharmaceutical Powder Blending in Both R&D and Manufacturing by Near-Infrared Spectroscopic (NIRS) Technology" is a government-funded research project for real-time quality control of manufacturing process, being a new pharmaceutical production technology in Hong Kong which can largely enhance the product quality and efficiency of the manufacturing process.

Approval was granted to another collaboration project with HKIB under government funding which will commence in early 2019. The project will study and explore the technology on the usage of Confocal Raman Microscope on specified manufacturing processes for providing the capability to precisely control and manage the manufacturing process to make sure the complicated formulation, ingredient distribution, and specified in-vivo efficacy can be achieved.

Collaboration with Nano & Advanced Materials Institute Limited (NAMI)

With the objective to extend the scope of application for this innovative nanotechnology on preclinical early Alzheimer detection, we have undertaken studies for new test development with encouraging progress from preliminary results. The new test developed from the study targets at research laboratories and groups not equipped with magnetic resonance imaging (MRI) facility by providing them with a more cost saving and versatile animal test method in drug research and development for Alzheimer's disease.

This collaborative research project with NAMI on "Novel Nanoparticles for Pre-clinical Diagnosis for Early Alzheimer Detection and Drug Development" has achieved encouraging recognition in its launch in June 2016 with the winning of the Gold Medal Award at the 45th International Exhibition of Inventions of Geneva.

ISSUANCE OF SHARES AND ACQUISITIONS

Issuance of Shares to Yunnan Baiyao

The Group entered into a subscription agreement with Yunnan Baiyao in respect of 200,000,000 new shares at the subscription price of HK\$2.06 per share. The Group completed the issuance of shares to Yunnan Baiyao on 3 September 2018. The net subscription price of each subscription share was approximately HK\$2.06, which was at a premium of approximately 13.81% to the closing price of HK\$1.810 as quoted on the Stock Exchange. The market price of the subscription shares was HK\$1.81 per share as quoted on the Stock Exchange on 14 August 2018, the date when the terms of the subscription agreement were fixed.

The gross proceeds of the subscription were approximately HK\$412,000,000. After deducting all related fees and expenses, the net proceeds from the subscription at approximately HK\$411,658,000 will be applied for funding potential merger and acquisitions, strategic alliances, in-licensing pharmaceutical or medical products to enrich the Group's product portfolio, expanding or upgrading our operating facilities as well as general working capital.

Acquisition of Melborn Property Limited (formerly known as Dickson Warehousing Limited)

On 23 August 2018, the Group has entered into an agreement with Dickson Concepts Limited, to acquire 100% equity interest in Melborn Property Limited (formerly known as Dickson Warehousing Limited) at a base consideration of HK\$250 million, subject to adjustment according to the agreement. This acquisition shall enhance the Group's logistics capacity as well as the operational efficiency of the Group to cater for future business growth. This acquisition was completed on 14 November 2018 and Melborn Property Limited (formerly known as Dickson Warehousing Limited) became a wholly-owned subsidiary of the Group.

Acquisition of 45% Equity Interest in Orizen Capital Limited

On 19 July 2018, the Group successfully acquired 45% equity interest of Orizen Capital Limited ("Orizen") at a consideration of HK\$118.7 million, after which Orizen and its subsidiary became associates of the Group. Our statement of profits or loss reflected a share of profits from associates of HK\$1.8 million for the period from 19 July 2018 to 30 September 2018. The operations of Orizen and its subsidiary strengthen the Group's presence in the traditional Chinese herbal medicines business segment and this acquisition enables the Group to build a more comprehensive product portfolio in the Chinese medicines segment.

REMUNERATION POLICY

As of 30 September 2018, the Group had a total of 1,803 employees (1,910 employees as at 30 September 2017). For the reporting period, the total staff costs of the Group was HK\$204.7 million, a reduction of HK\$7.8 million when compared to HK\$212.5 million for the six months ended 30 September 2017 due to enhancement of work efficiency. All the Group's employees have entered into standard employment contracts with the Group. Remuneration packages for the Group's employees in general comprise one or more of the following elements: basic salary, productivity-related incentives and work performance bonus. The Group sets out performance attributes for its employees based on their positions and job functions. It periodically reviews their work performance against the Group's strategic objectives and targets. The results of such reviews are taken into consideration when assessing salary adjustments, bonus awards, promotion, staff development plan and training need analysis. The Group provides various benefit schemes to its employees including annual leave entitlement, mandatory provident fund, group medical insurance and life insurance. Union has been established for the Group's employees in China according to local labour laws. As of 30 September 2018, the Group has not experienced any strikes or any labour disputes with its employees which would have or likely to have a material effect on its business.


The Group places high values on recruiting, developing and retaining its employees. It maintains high recruitment standards, provides competitive compensation and benefit packages to attract and retain talents. The Group also emphasizes on training and developing employees. In addition to different skill and knowledge based in-house training programs, the Group has training sponsorship policy to encourage its employees to attend external training for enhancing their job competencies.



FINANCIAL REVIEW

REVENUE

Revenue by Operating Segments




The increase in revenue of HK\$73.3 million or 9.9% compared to FY2018 Interim was contributed by the increase in revenue of HK\$53.1 million in Generic Drugs as well as HK\$30.7 million in Wholesale and Retail, offset by the decrease in revenue of HK\$10.5 million in Proprietary Medicines. Revenue split of the three segments was at the ratio of 72%, 14% and 14%.

In Generic Drugs segment, the increase in revenue reflected the higher revenue from both public sector and private sector, amounted to HK\$16.0 million and HK\$37.1 million respectively. The growth of revenue in public sector was primarily attributed to the demand in the existing tender products along with the contributions from newly awarded tenders. The growth in private sector mainly reflected the rise in average selling price and the organic growth in the demand.


In Proprietary Medicines segment, the decrease in revenue was mainly contributed by the combined effect of the increase in sales of Flying Eagle Woodlok Oil and Shiling Oil, offset by the decrease in sales of Ho Chai Kung brand products and Po Chai Pills.

Revenue by Geographic Location



Hong Kong continued to be the major revenue stream, representing 94% of the total revenue and contributed an increase in revenue of HK\$72.6 million. The slight increase in revenue from other overseas market was mainly due to the increase in export sales in Singapore and Canada which was offset by the decrease in sales in the USA.

Cost of Sales




Material cost continued to be the major component in the cost of goods sold which contributed to approximately 53.0% of the total cost of sales.



The decrease in staff cost of HK\$5.3 million or by 4.1% primarily reflected the decrease in number of headcount due to the cessation of production of a manufacturing plant in Chai Wan in July 2017.

The decrease in other production cost reflected the decrease in overheads due to the cessation of production of the above-mentioned manufacturing plant as well as the implementation of cost control measures carried out during the reporting period.

Profit from Operations



The profit from operations rose from HK\$112.7 million to HK\$158.6 million or by HK\$45.9 million or 40.7%. The enhancement in the profit from operations was principally contributed by the increase in gross profit of HK\$39.8 million, the decrease in selling and distribution expenses and administrative and other operating expenses by HK\$0.7 million and HK\$3.6 million respectively.


Finance Costs

The increase in finance costs mainly reflected the additional interests and amortisation arising from the convertible notes issued in October 2017.

Income Tax

The increase in income tax principally reflected the higher profit before taxation generated. The increase in effective tax rate was due to nondeductible finance costs arising from the convertible notes.

Profit Attributable to Shareholders



The increase in profit attributable to shareholders reflected the increase in profit from operations offset by the additional finance costs. The profit attributable to the shareholders increased by HK\$17.2 million or by 21.4% to HK\$97.5 million.

Assets

Property, Plant and Equipment

The increase in property, plant and equipment principally reflected the additions of HK\$11.3 million and the transfer from investment properties of HK\$62.0 million, and offset by the depreciation of HK\$44.0 million during the reporting period.

Intangible Assets

The decrease in intangible assets principally reflected amortisation of HK\$13.8 million and offset by the additions of HK\$6.0 million during the reporting period.

Inventories

The increase in inventories mainly represented the increase in inventories following the enhancement of production capacity.

Cash and Cash Equivalents

As at 30 September 2018, around 98.8% of cash and cash equivalents were denominated in Hong Kong dollars (as at 31 March 2018: 65.1%), while the remaining balances were denominated in United Stated dollars, Renminbi and Singapore dollars.



Liabilities

Bank Loans

The decrease in bank loans from HK\$903.9 million as at 31 March 2018 to HK\$818.9 million as at 30 September 2018 represented certain settlements of bank loans during the reporting period.

As at 30 September 2018 and 31 March 2018, all the bank loans of the Group were denominated in Hong Kong dollars.

USE OF PROCEEDS

Net proceeds of HK\$695.5 million were raised from the initial public offering of the Company (included proceeds from the over-allotment option exercised by the underwriter amounted to HK\$98.4 million and after the deduction of underwriting fees, commissions and expenses paid by us in connection with the initial public offering). The following table sets out the proposed application of the net proceeds and the actual usage up to 30 September 2018:

	Proposed application HK\$'000	Actual usage up to 30 September 2018 HK\$'000
Acquisitions – Expansion of businesses in Generic Drugs and Proprietary Medicines	139,108	139,108
Acquisitions – Enhancement of distribution network	104,331	26,926
Acquisitions – Intangible assets	69,554	69,000
Capital investments – Upgrading of manufacturing plants and facilities	113,197	113,197
Capital investments – Two specific automated production facilities	12,000	12,000
Expansion of bioequivalence clinical studies	94,331	24,015
Establishment of a new joint R&D centre with HKIB	10,000	2,121
Marketing and advertising	83,465	47,248
General working capital	69,554	69,554
	695,540	503,169

Net proceeds of HK\$490,352,000 were raised from the issuance of convertible notes (after deduction of all related fees and expenses paid by us in connection with the convertible notes of HK\$9,648,000). The net proceeds are intended to be used for funding potential merger and acquisitions as well as forming strategic alliances in the Asia Pacific region. The proceeds will also be used for supporting in-licensing and direct investment on technologically-oriented bio-pharmaceutical projects. The actual usage up to 30 September 2018 was HK\$255,863,000.

Net proceeds of HK\$411,658,000 were raised from the issuance of shares to Yunnan Baiyao (after the deduction of all related fees and expenses payable in connection with the issuance of shares of HK\$342,000). The following table sets out the proposed application of the net proceeds and the actual usage up to 30 September 2018:

	Proposed application	Actual usage up to 30 September 2018
	НК\$'000	HK\$'000
Merger and acquisitions, strategic alliances and in-licence of products	205,829	-
Acquisition, expansion and upgrading of operating facilities	164,663	122,100
General working capital	41,166	186
	411,658	122,286

LIQUIDITY, CAPITAL RESOURCES AND CAPITAL STRUCTURE

The Group consistently adheres to conservative fund management. The solid capital structure and financial strength continue to provide a solid foundation for the Group's future development.

The Group's primary uses of cash are to fund working capital and capital expenditures. During the reporting period, the Group funded its cash requirements principally from cash generated from operations and funds raised from the Listing, bank borrowings, the issuance of convertible notes and the issuance of Shares to Yunnan Baiyao.

CHARGE ON GROUP ASSETS

The carrying value of assets pledged against bank loans decreased from HK\$464.0 million as at 31 March 2018 to HK\$462.0 million as at 30 September 2018.

NET GEARING RATIO

The net gearing ratio of the Group (bank loans and convertible notes less cash and cash equivalents, divided by total equity multiplied by 100%) decreased from 34.6% as of 31 March 2018 to 18.9% as of 30 September 2018. The decrease in net gearing ratio was attributable to the issuance of shares in the reporting period.

FINANCIAL RISK ANALYSIS

Management considered that the Group did not have significant exposure to fluctuation in exchange rates and any related hedges.



CONTINGENT LIABILITIES

As of 30 September 2018, the Group did not have any significant contingent liabilities.

NON-ADJUSTING EVENTS AFTER THE REPORTING PERIOD

On 23 August 2018, the Group has entered into an agreement with Dickson Concepts Limited, to acquire 100% equity interest in Melborn Property Limited (formerly known as Dickson Warehousing Limited) at a base consideration of HK\$250 million, which is subject to adjustment according to the agreement. This acquisition was subsequently completed on 14 November 2018 and Melborn Property Limited became a wholly-owned subsidiary of the Group.

For details, please refer to the announcements of the Company dated 23 August 2018 and 14 November 2018.

PRINCIPAL RISKS AND UNCERTAINTIES

The following is a summary of the principal risks and uncertainties identified by the Company which may have material and adverse impact on its business or operation, and how the Company endeavours to manage the risks involved. There may be other principal risks and uncertainties in addition to those shown below which are not known to the Company or which may not be material now but could turn out to be material in the future.

- The Group operates in pharmaceutical manufacturing industry and is subject to various regulations; failure to comply with pharmaceutical
 or other regulations may restrict our business operations. The Group has dedicated quality control and quality assurance team in each
 manufacturing plant to ensure compliance with relevant regulations.
- The Group made a number of successful acquisitions; however the Group may not be able to successfully identify, consummate and integrate future mergers or acquisitions. The Group will continue to seek for new acquisition opportunities and perform adequate due diligence to assess the potential acquisition targets.
- The Group operates in generic drugs business and development of new products provides additional growth driver for the Group. However, we
 may not be able to develop and launch new product according to our schedule. The Group continues to invest in the research and development
 of new products and engage external experts to enhance our overall R&D capability.
- The Group is also exposed to risks of liability and loss due to defective products as well as damage to the Group's reputation. While the Group has taken out product liability insurance, the insured amount may not be sufficient to cover all damages claimed. The Group has a designated production and quality assurance team to monitor product quality in each plant to ensure they are in compliance with respective specifications.

The Company believes that risk management is essential to the Group's efficient and effective operation. The Company's management assists the Board in evaluating material risk exposure in the Group's business, participating in formulating appropriate risk management and internal control measures, and ensuring its implementation in the daily operational management.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is primarily engaged in manufacturing generic drugs and proprietary medicines, a line of business that does not have any material impact on the environment. The key environmental impact from the Group's operation are related to electricity, water and paper consumption. The Group is fully aware of the importance of sustainable environmental development, and has implemented a number of measures to encourage environmental protection and energy conservation.

During the reporting period, there was no significant regulatory non-compliance with applicable environmental laws and regulations.

COMPLIANCE WITH LAWS AND REGULATIONS

During the reporting period, the Group is in compliance with the applicable laws and regulations which have significant impacts on the Group in all material respects.

OTHER INFORMATION

CORPORATE GOVERNANCE HIGHLIGHTS

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code of corporate governance.

During the reporting period, the Company has complied with all the code provisions of the CG Code and adopted most of the best practices set out therein, except for the following provision:

Code provision A.2.1 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing.

Currently, Mr. Sum is the chairman of the Board and the chief executive officer of the Company and accordingly, there is no written terms setting out the division of responsibilities between the chairman and chief executive. The Board considers that Mr. Sum is the founder of the Group and had been managing the Group's business and overall strategic planning since its establishment, the vesting of the roles of chairman and chief executive officer in Mr. Sum is beneficial to the business prospects and management of the Group by ensuring consistent leadership within the Group and enabling more effective and efficient overall strategic planning for the Group. The Board also considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively.

The Board will continue to review and consider splitting the roles of chairman of our Board and the chief executive officer of the Company at an appropriate time, taking into account the circumstances of the Group as a whole.

To comply with the new Listing Rules that are to be effective from 1 January 2019, the Board has approved to adopt a dividend policy and a Director nomination policy, and to revise the terms of reference of each of the Audit Committee and Nomination Committee and the Board diversity policy with effect from 1 January 2019.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding securities transactions of the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the required standard as set out in the Model Code throughout the reporting period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor its subsidiaries has purchased, sold or redeemed any of the Company's listed securities throughout the reporting period.

AUDIT COMMITTEE

The Board has established an audit committee (the "Audit Committee") which comprises three independent non-executive Directors, namely Mr. Young Chun Man, Kenneth (Chairman), Dr. Lam Kwing Tong, Alan and Professor Wong Chi Kei, Ian. The primary duties of the Audit Committee include reviewing and supervising the Group's financial reporting process, internal control and risk management systems, preparing financial statements and internal control procedures. It also acts as an important link between the Board and the external auditor in matters within the scope of the group audit.

REVIEW OF INTERIM RESULTS

The interim results for the six months ended 30 September 2018 are unaudited, but have been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included on page 27.

The Audit Committee, together with management of the Company, has also reviewed the interim results for the six months ended 30 September 2018.



INTERIM DIVIDEND

The Board recommends a payment of an interim dividend per ordinary share for the six months ended 30 September 2018 of HK1.5 cents for the total amount of approximately HK\$30.2 million (six months ended 30 September 2017: HK0.9 cent). The interim dividend will be paid on 21 December 2018 (Friday) to shareholders whose names appear on the register of members of the Company on 10 December 2018 (Monday), the record date. The details of interim dividend of the Group are set out in note 9 of the unaudited the interim financial report.

CLOSURE OF REGISTER OF MEMBERS

In order to determine the entitlement of shareholders of the Company to receive the interim dividend, the register of members of the Company will be closed from 7 December 2018 (Friday) to 10 December 2018 (Monday), both days inclusive, during which period no transfer of shares of the Company will be registered. All transfer documents, accompanied by the relevant share certificate, shall be lodged with the Company's Hong Kong Branch Share Registrar at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than 4:30 p.m. on 6 December 2018 (Thursday).

GENERAL DISCLOSURE PURSUANT TO LISTING RULES

Pursuant to Rules 13.18 and 13.21 of the Listing Rules, the Company discloses the following information:

On 6 September 2017, the Company entered into the subscription agreements with each of the two subscribers thereby the subscribers agreed to subscribe for the 3.5% convertible notes in an aggregate principal amount of HK\$500 million due 2020 and the subscriptions for the convertible notes were completed on 3 October 2017. Based on the initial conversion price of HK\$2.50 per conversion share, a maximum of 200,000,000 shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the convertible notes in full.

As the convertible notes provided, among other things, a specific performance obligation on the controlling shareholder of the Company, Mr. Sum, to maintain his status as the single largest controlling shareholder of the Company and a cessation of such status will result in a default therein.

As at 30 September 2018, the aggregate principal amount under the above convertible notes was HK\$500 million.

For details, please refer to the announcements of the Company dated 6 September 2017 and 3 October 2017.

CHANGE OF INFORMATION ON DIRECTORS

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes and updated information regarding the Directors of the Company since the Company's last published annual report and up to the date of this interim report are set out below:

- (a) Professor Lam Sing Kwong, Simon, a non-executive Director of the Company, whose director's fee was revised from HK\$208,000 to HK\$220,000 per annum with effect from 1 January 2019;
- (b) Dr. Lam Kwing Tong, Alan, an independent non-executive Director of the Company, whose director's fee was revised from HK\$208,000 to HK\$220,000 per annum with effect from 1 January 2019;
- (c) Mr. Young Chun Man, Kenneth, an independent non-executive Director of the Company, whose director's fee was revised from HK\$208,000 to HK\$220,000 per annum with effect from 1 January 2019;
- (d) Professor Wong Chi Kei, Ian, an independent non-executive Director of the Company, whose director's fee was revised from HK\$208,000 to HK\$220,000 per annum with effect from 1 January 2019. Professor Wong's appointment as the Head of Research of Practice and Policy at University College London has been ended in July 2018;
- (e) **Mr. Sum Kwong Yip, Derek**, an executive Director of the Company, has been appointed by the Board as the chairman of the share award committee of the Company in respect of the new share award scheme of the Company as adopted on 16 October 2018; and
- (f) **Mr. Yim Chun Leung**, an executive Director of the Company, has been appointed by the Board as a member of the share award committee of the Company in respect of the new share award scheme of the Company as adopted on 16 October 2018.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 September 2018, the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, including interests or short positions which they were taken or deemed to have under such provisions of the SFO, or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which were required to be notified to the Company and the Stock Exchange pursuant to section 347 of the SFO and the Model Code were as follows:

(I) INTERESTS IN SHARES OF THE COMPANY

Name of Director	Capacity/Nature of Interest	Number of shares	Approximate percentage of issued share capital of the Company	Long position/ Short position/ Lending pool
Mr. Sum ⁽¹⁾⁽²⁾	Interests in controlled corporation Settlor of trusts Beneficiary of trusts	1,288,399,000	63.92%	Long position
Mr. Yim Chun Leung	Beneficial owner	26,150,000	1.30%	Long position
Ms. Pun Yue Wai	Beneficial owner	1,460,000	0.07%	Long position
Dr. Lam Kwing Tong, Alan	Interests of children under 18 and/or spouse	440,000	0.02%	Long position

Notes:

- (1) Mr. Sum is the sole shareholder of The Jacobson Pharma (PTC) Limited, being the trustee of the trust established for the purpose of holding the shares under the Share Incentive Scheme. Queenshill is the settlor of such trust. By virtue of the SFO, Mr. Sum and Queenshill are deemed to be interested in the 12,015,000 shares held by The Jacobson Pharma (PTC) Limited. Mr. Sum is also the sole shareholder of Queenshill.
- (2) UBS Trustees (B.V.I) Limited, the trustee of The Kingshill Trust, holds the entire issued share capital of Kingshill Development Group Inc. ("Trust Co") through its nominee, UBS Nominees Limited. Trust Co holds the entire issued share capital of Kingshill. Kingshill in turn holds 850,684,000 shares in the Company. The Kingshill Trust is a discretionary trust established by Mr. Sum (as the settlor) with Mr. Sum and his family members as the discretionary beneficiaries (directly and through The Queenshill Trust). By virtue of the SFO, Mr. Sum, as the settlor and a discretionary beneficiary of The Kingshill Trust and The Queenshill Trust, is deemed to be interested in the 850,684,000 Shares held by Kingshill.

(II) INTERESTS IN UNDERLYING SHARES OF THE COMPANY HELD THROUGH SHARE OPTIONS

Share options were granted to two executive Directors under the share option scheme adopted by the shareholders of the Company on 30 August 2016 (the "Share Option Scheme").

As at 30 September 2018, Directors had personal interests in the following underlying shares of the Company held through share options granted under the Share Option Scheme:

Name of Director	Capacity in which such interests were held	Number of underlying ordinary shares	Approximate percentage of issued voting shares
Mr. Yim Chun Leung	Beneficial owner	13,500,000	0.66%
Ms. Pun Yue Wai	Beneficial owner	4,500,000	0.22%

Further details of share options granted to Directors under the Share Option Scheme are set out in the section headed "Share Option Scheme" below.

These interests in share options represented long positions in the underlying shares in respect of physically settled derivatives of the Company. Interests of the Directors, Mr. Yim Chun Leung and Ms. Pun Yue Wai, set out in this subsection (II) shall be aggregated with their respective interests in the shares of the Company set out in subsection (I) above in order to give the total interests of the Director in the Company pursuant to the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.



Save as disclosed above, so far as known to any Directors as at 30 September 2018, none of the Directors or chief executive of the Company or any of their close associates had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, including interests and short positions which they were taken or deemed to have under such provisions of the SFO, or which were required to be recorded in the register to be kept by the Company pursuant to section 347 of the SFO and the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 September 2018, within the knowledge of the Directors, the following persons or corporations had or deemed or taken to have an interest or a short position in the shares or underlying shares of the Company which were required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

(I) INTERESTS IN SHARES OF THE COMPANY

Name of Shareholder	Nature of Interest	Number of shares	Approximate percentage of issued share capital of the Company	Long position/ Short position/ Lending pool
Queenshill ⁽¹⁾	Beneficial owner Settlor of a trust	280,665,000	13.92%	Long position
Kingshill ^[2]	Beneficial owner Interest held jointly with another person	1,007,734,000	50.00%	Long position
Longjin ^[2]	Beneficial owner Interest held jointly with another person	1,007,734,000	50.00%	Long position
Trust Co ⁽³⁾	Trust holding company	1,007,734,000	50.00%	Long position
UBS Trustees (B.V.I.) Limited ⁽³⁾	Trustee	1,007,734,000	50.00%	Long position
Mr. Lau ^[2]	Interest in controlled corporation	1,007,734,000	50.00%	Long position
Mr. Sum ⁽¹⁾⁽³⁾	Interest in controlled corporation Settlor of trusts Beneficiary of trusts	1, 288,399,000	63.92%	Long position
Yunnan Baiyao ^[4]	Beneficial owner	200,000,000	9.92%	Long position
State-owned Assets Supervision and Administration Commission of Yunnan Provincial People's Government* (雲南省人民政府國有資產監督 管理委員會) ^[5]	Interest in controlled corporation	200,000,000	9.92%	Long position
New Huadu Industrial Group Co., Ltd.* (新華都實業集團股份有限公司) ^[6]	Interest in controlled corporation	200,000,000	9.92%	Long position
Mr. Chen Fa Shu ^[6]	Interest in controlled corporation	200,000,000	9.92%	Long position

Notes:

- (1) Mr. Sum is the sole shareholder of The Jacobson Pharma (PTC) Limited, being the trustee of the trust established for the purpose of holding the shares under the Share Incentive Scheme. Queenshill is the settlor of such trust. By virtue of the SFO, Mr. Sum and Queenshill are deemed to be interested in the 12,015,000 shares held by The Jacobson Pharma (PTC) Limited. Mr. Sum is also the sole shareholder of Queenshill.
- (2) Kingshill and Longjin are parties acting in concert pursuant to the Deed of Acting in Concert and hence each of them is deemed to be interested in the Shares held by each others. Please refer to the section headed "Relationship with our Controlling Shareholders" of the Prospectus for further details. Kingshill is wholly-owned by Trust Co under The Kingshill Trust, a discretionary trust established by Mr. Sum (as the settlor). Longjin is owned as to 75% by Mr. Lau.
- (3) UBS Trustees (B.V.I.) Limited, the trustee of The Kingshill Trust, holds the entire issued share capital of Trust Co through its nominee, UBS Nominees Limited. Trust Co holds the entire issued share capital of Kingshill. Kingshill in turn holds 850,684,000 Shares in the Company. The Kingshill Trust is a discretionary trust established by Mr. Sum (as the settlor) with Mr. Sum and his family members as the discretionary beneficiaries (directly and through The Queenshill Trust). By virtue of the SFO, each of Mr. Sum, UBS Trustees (B.V.I.) Limited, Trust Co and Kingshill is deemed to be interested in the 850,684,000 Shares held by Kingshill.
- (4) Pursuant to the subscription agreement dated 14 August 2018 entered into by Yunnan Baiyao and the Company in relation to the subscription of 200,000,000 new ordinary shares at the subscription price of HK\$2.06 per share. 200,000,000 new ordinary shares were issued to Yunnan Baiyao on 3 September 2018. For details of the subscription and issuance of 200,000,000 new ordinary shares, please refer to the announcements of the Company dated 14 August 2018 and 3 September 2018 respectively.
- (5) State-owned Assets Supervision and Administration Commission of Yunnan Provincial People's Government* (雲南省人民政府國有資產監督管理 委員會) holds 45% of the voting shares of Yunnan Baiyao and therefore it is deemed to be interested in Yunnan Baiyao and the 200,000,000 shares held by Yunnan Baiyao.
- (6) Mr. Chen Fa Shu holds 76.87% of the voting shares in New Huadu Industrial Group Co., Ltd. * (新華都實業集團股份有限公司), which in turn holds 45% of the voting shares in Yunnan Baiyao and therefore Mr. Chen Fa Shu and New Huadu Industrial Group Co., Ltd. * (新華都實業集團股份有限公司) are deemed to be interested in Yunnan Baiyao and the 200,000,000 shares held by Yunnan Baiyao.

* For purpose of identification only.



(II) INTERESTS IN UNDERLYING SHARES OF THE COMPANY HELD THROUGH THE SUBSCRIPTION FOR CONVERTIBLE NOTES

On 6 September 2017, the Company entered into subscription agreements with two subscribers where Dragons 615 Limited was one of the subscribers and pursuant to which Dragons 615 Limited has agreed to subscribe for the convertible notes in a principal amount of HK\$280 million at an initial price of HK\$2.50 per share. The Company completed the issuance of the convertible notes on 3 October 2017. For details, please refer to the announcements of the Company dated 6 September 2017 and 3 October 2017.

As at 30 September 2018, interests in the underlying shares of the Company held through the subscription for convertible notes were as follows:

Name of Shareholder	Nature of interests	Number of underlying ordinary shares	Approximate percentage of issued voting shares
DCP China Credit Fund I, L.P.	Interest in controlled corporation	112,000,000 ^(Note)	5.56%
Dignari Capital Partners GP Limited	Interest in controlled corporation	112,000,000 ^(Note)	5.56%
Ms. Tan Mei Zie Grace	Interest in controlled corporation	112,000,000 ^(Note)	5.56%

Note:

Dragons 615 Limited was a wholly-owned limited liability company of DCP China Credit Fund I, L.P. whose general partner was Dignari Capital Partners GP Limited, and Ms. Tan Mei Zie Grace had the deemed interests in controlled corporation.

Save as disclosed above, as at 30 September 2018, the Directors are not aware of any other person (other than the Directors or chief executive of the Company) who had an interest or short position in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

SHARE OPTION SCHEME

The Share Option Scheme of the Company was adopted by shareholders of the Company on 30 August 2016.

A summary of the Share Option Scheme is as follows:

The purpose of the Share Option Scheme is to provide an incentive for the qualified participants to work with commitment towards enhancing the value of our Company and its shares for the benefit of its shareholders, and to maintain or attract business relationship with the qualified participants whose contributions are or may be beneficial to the growth of our Group.

The participants of the Share Option Scheme include any directors, employees (whether full-time or part-time) of the Group, and any customer, business or joint venture partner, advisor, consultant, supplier, agent, service provider of our Group or any full-time employee of them, who the Directors consider, in their sole discretion, has contributed or will contribute to our Group.

The life of the Share Option Scheme is ten years commencing on 30 August 2016 and expiring on 29 August 2026. As at 30 September 2018, the outstanding share options under the Share Option Scheme available for issue of ordinary shares was 138,000,000 shares representing approximately 6.85% of the issued shares of the Company as at the date of this interim report.

There is no minimum period for which any option under the Share Option Scheme must be held before it can be exercised and no performance target which need to be achieved by a grantee before the option can be exercised unless the Directors otherwise determined and stated in the offer letter of the grant of options.

An offer of the grant of option shall remain open (not exceeding 30 days, inclusive of, and from, the date of offer) as the Directors may determine for acceptance by a grantee at a consideration of HK\$1 for the grant.

The maximum entitlement of each participant under the Share Option Scheme if the acceptance of those options would result in the total number of shares issued and to be issued to that grantee on exercise of his/her options (including both exercised and outstanding options) during any 12-month period exceeding 1% of the total shares of the Company then in issue.

The subscription price shall be a price determined by the Directors but in any event shall be at least the highest of (i) the closing price of the shares of the Company as stated in the Stock Exchange's daily quotations sheets on the date of offer; (ii) the average of the closing prices of the shares of the Company as stated in the Stock Exchange's daily quotations sheets for the five business days immediately preceding the date of offer; and (iii) the nominal value of the shares of the Company.

Since the effective date of the Share Option Scheme and up to 30 September 2018, the Company has granted a total of 37,000,000 share options to eligible grantees, including certain Directors and employees of the Group, on 30 June 2017 and 18 October 2017, while a total of 900,000 share options were lapsed and no share option had been exercised under the Share Option Scheme. Details of the movement in the share options under the Share Option Scheme during the reporting period and outstanding as at 30 September 2018 were as follows:

	Number of options outstanding at 1 April 2018	Number of options granted during the reporting period	Number of ordinary shares acquired upon exercise of options during the reporting period	Number of options lapsed during the reporting period	Number of options cancelled during the reporting period	Number of options outstanding at 30 September 2018	Date granted	Exercise price per ordinary share	Exercisable period
Directors:									
Mr. Yim Chun Leung	13,500,000	-	-	-	-	13,500,000	30 June 2017	HK\$2.06	from 1 October 2017 up to 30 September 2020 in three tranche
Ms. Pun Yue Wai	4,500,000	-	-	-	-	4,500,000	30 June 2017	HK\$2.06	from 1 October 2017 up to 30 September 2020 in three trancher
sub-total	18,000,000	-	-	-	-	18,000,000			
All other employees:	17,600,000	-	-	500,000	-	17,100,000	30 June 2017	HK\$2.06	from 1 October 2017 up to 30 September 2020 in three tranches
	1,000,000	-	-	-	-	1,000,000	18 October 2017	HK\$2.13	from 18 October 2017 up to 17 October 2020 subject to the vesting date on 1 April 2018
sub-total	18,600,000	-	_	500,000	-	18,100,000			
Grand Total	36,600,000	_	_	500,000	_	36,100,000			

The share options granted on 30 June 2017 are valid and exercisable within a validity period from 1 October 2017, 2018 and 2019 up to 30 September 2018, 2019 and 2020 respectively in three tranches and any outstanding Options that the grantee has not exercised during the period for the respective tranche shall lapse automatically upon the expiry of the period for the respective tranche. Whereas, the share options granted on 18 October 2017 are valid for three years commencing from 18 October 2017 up to 17 October 2020 and are exercisable subject to the vesting date on 1 April 2018 and any outstanding Options that the grantee has not exercised during the period shall lapse automatically upon the expiry of the period.



SHARE INCENTIVE SCHEME

The Share Incentive Scheme of the Company was adopted by shareholders of the Company on 30 August 2016 which became effective on the Company's date of Listing, to recognize the contributions by certain eligible persons and to give incentives in order to motivate and retain them for the continuing operation, development and long-term growth of the Group and to attract suitable personnel for further development of the Group. For details of the Share Incentive Scheme, please refer to Appendix V to the Company's prospectus. During the reporting period, no Director was granted share awards entitling the Director to acquire ordinary shares of the Company.

ARRANGEMENT TO PURCHASE SHARES OR DEBENTURES

Other than the sections headed "Share Option Scheme" and "Share Incentive Scheme", at no time during the reporting period was the Company or any of its subsidiaries, a party to any arrangement to enable the Directors to acquire benefits by means of the acquisition of shares in, or debt securities including debentures of, the Company or any other body corporate.

Review Report to the Board of Directors

Review report to the board of directors Jacobson Pharma Corporation Limited

(Incorporated in the Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial report set out on pages 28 to 46 which comprises the consolidated statement of financial position of Jacobson Pharma Corporation Limited (the "Company") as of 30 September 2018 and the related consolidated statement of profit or loss and other comprehensive income and statement of changes in equity and condensed consolidated cash flow statement for the six-month period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants. The directors are responsible for the preparation and presentation of the interim financial report in accordance with Hong Kong Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed* by the independent auditor of the entity, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 September 2018 is not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34, *Interim financial reporting*.

KPMG *Certified Public Accountants*

8th Floor, Prince's Building 10 Chater Road Central, Hong Kong 21 November 2018



		Six months ended 30 September		
		2018	2017	
	Note	HK\$'000	HK\$'000	
Revenue	4	816,260	743,032	
Cost of sales		(497,566)	(464,128)	
Gross profit	F	318,694	278,904	
Other net income Selling and distribution expenses	5	5,480 (83,233)	3,702 (83,962)	
Administrative and other operating expenses		(82,297)	(85,940)	
Profit from operations Finance costs	6(A)	158,644 (33,252)	112,704 (13,874)	
Share of profits of associates	0(A)	1,819	(13,074)	
Profit before taxation	6	127,211	98,830	
Income tax	o 7	(23,835)	(15,762)	
	7			
Profit for the period		103,376	83,068	
Other comprehensive income for the period				
Item that will not be reclassified to profit or loss:		0/ 001		
Revaluation of financial assets at fair value through other comprehensive income		96,201	-	
Item that may be reclassified to profit or loss:				
Exchange differences on translation of financial statements of				
operations outside Hong Kong		(4,096)	1,496	
Other comprehensive income for the period		92,105	1,496	
Total comprehensive income for the period		195,481	84,564	
Profit attributable to:				
Shareholders of the Company		97,531	80,329	
Non-controlling interests		5,845	2,739	
Total profit for the period		103,376	83,068	
Total comprehensive income attributable to:				
Shareholders of the Company		189,636	81,825	
Non-controlling interests		5,845	2,739	
Total comprehensive income for the period		195,481	84,564	
		HK cents	HK cents	
Earnings per share			The cents	
Basic and diluted	8	5.28	4.42	

Note: The Group has initially applied Hong Kong Financial Reporting Standard ("HKFRS") 15 and HKFRS 9 at 1 April 2018. Under the transition methods chosen, comparative information is not restated.

Details of dividends payable to shareholders of the Company are set out in note 9.

Consolidated Statement of Financial Position

At 30 September 2018 – unaudited (Expressed in Hong Kong dollars)

		As at 30 September 2018	As at 31 March 2018
	Note	HK\$'000	HK\$'000
Non-current assets			
Investment properties	10	161,400	91,000
Other property, plant and equipment	10	1,008,435	982,270
Leasehold land		46,936	48,041
Intangible assets		1,079,358	1,087,140
Interest in associates		151,889	12,603
Other non-current assets		58,902	26,510
Other financial assets		218,419	117,718
Deferred tax assets		6,377	4,191
		2,731,716	2,369,473
Current assets			
Inventories		324,878	316,323
Trade and other receivables	11	260,028	254,797
Current tax recoverable		8,256	13,829
Cash and cash equivalents	12	791,402	656,733
		1,384,564	1,241,682
Current liabilities			
Trade and other payables	13	112,625	105,553
Bank loans		590,804	903,872
Obligations under finance leases		184	184
Convertible notes		456,853	447,097
Current tax payable		23,207	4,657
		1,183,673	1,461,363
Net current assets/(liabilities)		200,891	(219,681)
Total assets less current liabilities		2,932,607	2,149,792
Non-current liabilities			
Banks loans		228,107	-
Obligations under finance leases		568	660
Deferred tax liabilities		143,459	141,157
		372,134	141,817
NET ASSETS		2,560,473	2,007,975
CAPITAL AND RESERVES	14		
Share capital		20,156	18,156
Reserves		2,502,259	1,957,606
Total equity attributable to shareholders of the Company		2,522,415	1,975,762
Non-controlling interests		38,058	32,213
TOTAL EQUITY		2,560,473	2,007,975



Consolidated Statement of Changes in Equity For the six months ended 30 September 2018 – unaudited (Expressed in Hong Kong dollars)

				Attributable to	shareholders of	the Company				
	-					Fair value reserve			Non-	
	Note	Share capital HK\$'000	Share premium HK\$'000	Capital reserve HK\$'000	Exchange reserve HK\$'000	(non- recycling) HK\$'000	Retained earnings HK\$'000	Total HK\$'000	controlling interests HK\$'000	Total equity HK\$'000
At 1 April 2017		18,156	717,058	90,564	3,942	-	919,683	1,749,403	22,915	1,772,318
Profit for the period Other comprehensive income		-	-	-	- 1,496	- -	80,329 -	80,329 1,496	2,739 -	83,068 1,496
Total comprehensive income for the period		-	-	-	1,496	-	80,329	81,825	2,739	84,564
Acquisition of subsidiaries Dividend paid Equity settled share-based transactions	9(B) 14(B)	- - -	- - -	- - 3,500	- - -	- - -	- (25,419) -	- (25,419) 3,500	7,021 - -	7,021 (25,419) 3,500
At 30 September 2017		18,156	717,058	94,064	5,438	-	974,593	1,809,309	32,675	1,841,984
At 1 April 2018		18,156	717,058	152,768	7,587	-	1,080,193	1,975,762	32,213	2,007,975
Profit for the period Other comprehensive income		-	-	-	- (4,096)	- 96,201	97,531 -	97,531 92,105	5,845 -	103,376 92,105
Total comprehensive income for the period		-	-	-	(4,096)	96,201	97,531	189,636	5,845	195,481
Issuance of new shares Dividend paid Equity settled share-based transactions	14(A) 9(B) 14(B)	2,000 - -	409,658 - -	- - 3,812	-	-	- (58,453) -	411,658 (58,453) 3,812	- - -	411,658 (58,453) 3,812
At 30 September 2018		20,156	1,126,716	156,580	3,491	96,201	1,119,271	2,522,415	38,058	2,560,473

Condensed Consolidated Cash Flow Statement For the six months ended 30 September 2018 – unaudited (Expressed in Hong Kong dollars)

		Six months ended 30 S	eptember
		2018	2017
	Note	HK\$'000	HK\$'000
Operating activities			
Cash generated from operations		208,948	127,109
Income tax refunded/(paid)		243	(494)
Net cash generated from operating activities		209,191	126,615
Investing activities			
Payment for purchase of property, plant and equipment,			
investment properties and intangible assets		(167,853)	(94,739)
Proceeds from disposals of property, plant and equipment		556	1,277
Net cash outflow from acquisition of subsidiaries under business combination		-	(38,992)
Payment for purchase of other financial assets		(4,500)	-
Payment for acquisition of associates		(137,467)	-
Increase in non-current prepayments		(10,000)	
Other cash flows arising from investing activities		1,265	51
Net cash used in investing activities		(317,999)	(132,403)
Financing activities			
Proceeds from bank loans		282,740	403,540
Repayment of bank loans		(367,701)	(391,597)
Proceeds from shares issued	14(A)	411,658	-
Dividends paid	9(B)	(58,453)	(25,419)
Other cash flows arising from financing activities		(23,588)	(14,234)
Net cash generated from/(used in) financing activities		244,656	(27,710)
Net increase/(decrease) in cash and cash equivalents		135,848	[33,498]
Cash and cash equivalents at 1 April	12	656,733	359,685
Effect of foreign exchange rate changes		(1,179)	153
Cash and cash equivalents at 30 September	12	791,402	326,340



Notes to the Unaudited Interim Financial Report

(Expressed in Hong Kong dollars unless otherwise indicated)

1 Corporate information

Jacobson Pharma Corporation Limited (the "Company") is an exempted company with limited liability incorporated in the Cayman Islands. The Company is an investment holding company. The Company and its subsidiaries (the "Group") is principally engaged in manufacturing and trading of generic drugs and proprietary medicines. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on 21 September 2016.

2 Basis of preparation

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("HKAS") 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). It was authorised for issue on 21 November 2018.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the consolidated financial statements for the year ended 31 March 2018, except for the accounting policy changes that are expected to be reflected in the consolidated financial statements for the year ending 31 March 2019. Details of any changes in accounting policies are set out in note 3.

The preparation of an interim financial report in conformity with HKAS 34 requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2017/18 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for full set of financial statements prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs").

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA. KPMG's independent review report to the Board of Directors is included on page 27.

3 Changes in accounting policies

(A) OVERVIEW

The HKICPA has issued a number of new HKFRSs and amendments to HKFRSs that are first effective for the current accounting period of the Group. Of these, the following developments are relevant to the Group's financial statements:

- HKFRS 9, Financial instruments
- HKFRS 15, Revenue from contracts with customers
- HK(IFRIC) 22, Foreign currency transactions and advance consideration

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

The Group has been impacted by HKFRS 9 in relation to classification of financial assets and measurement of credit losses, and impacted by HKFRS 15 in relation to timing of revenue recognition, capitalisation of contract costs, significant financing benefit obtained from customers and presentation of contract assets and contract liabilities. Details of the changes in accounting policies are discussed in note 3(B) for HKFRS 9 and note 3(C) for HKFRS 15.

Under the transition methods chosen, the Group recognises cumulative effect of the initial application of HKFRS 9 and HKFRS 15 as an adjustment to the opening balance of equity at 1 April 2018. Comparative information is not restated.

3 Changes in accounting policies (Continued)

(B) HKFRS 9, FINANCIAL INSTRUMENTS

HKFRS 9 replaces HKAS 39, *Financial instruments: recognition and measurement*. It sets out the requirements for recognising and measuring financial assets, financial liabilities and some contracts to buy or sell non-financial items.

The Group has applied HKFRS 9 retrospectively to items that existed at 1 April 2018 in accordance with the transition requirements. The Group has recognised the cumulative effect of initial application as an adjustment to the opening equity at 1 April 2018. Therefore, comparative information continues to be reported under HKAS 39.

Further details of the nature and effect of the changes to previous accounting policies and the transition approach are set out below:

(i) Classification of financial assets and financial liabilities

HKFRS 9 categories financial assets into three principal classification categories: measured at amortised cost, at fair value through other comprehensive income ("FVOCI") and at fair value through profit or loss ("FVPL"). These supersede HKAS 39's categories of held-to-maturity investments, loans and receivables, available-for-sale financial assets and financial assets measured at FVPL. The classification of financial assets under HKFRS 9 is based on the business model under which the financial asset is managed and its contractual cash flow characteristics.

An investment in equity securities is classified as FVPL unless the equity investment is not held for trading purposes and on initial recognition of the investment the Group makes an election to designate the investment at FVOCI such that subsequent changes in fair value are recognised in other comprehensive income. Such elections are made on an instrument-by-instrument basis, but may only be made if the investment meets the definition of equity from the issuer's perspective. Where such an election is made, the amount accumulated in other comprehensive income remains in the fair value reserve until the investment is disposed of. At the time of disposal, the amount accumulated in the fair value reserve is transferred to retained earnings. It is not recycled through profit or loss. Dividends from an investment in equity securities, irrespective of whether classified as at FVPL or FVOCI, are recognised in profit or loss as other income.

Upon the initial application of HKFRS 9, available-for-sale equity securities of HK\$117,718,000 at 31 March 2018, which were stated at cost less impairment losses and included in other financial assets in the statement of financial position, were reclassified as financial assets at FVOCI at 1 April 2018. Management determined that the fair value of the equity securities approximated the carrying value at 1 April 2018 and accordingly, there was no adjustment to the Group's opening equity as at 1 April 2018.

The measurement categories for all financial liabilities remain the same. The carrying amounts for all financial liabilities at 1 April 2018 have not been impacted by the initial application of HKFRS 9.

(ii) Credit losses

HKFRS 9 replaces the "incurred loss" model in HKAS 39 with the expected credit losses ("ECL") model. The ECL model requires an ongoing measurement of credit risk associated with a financial asset and therefore recognises ECLs earlier than under the "incurred loss" accounting model in HKAS 39.

The Group applies the new ECL model to the financial assets measured at amortised cost (including cash and cash equivalents and trade and other receivables). Financial assets measured at fair value are not subject to the ECL assessment.

Measurement of ECLs

ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all expected cash shortfalls (i.e. the difference between the cash flows due to the Group in accordance with the contract and the cash flows that the Group expects to receive).

The expected cash shortfalls of trade and other receivables are discounted using the effective interest rate determined at initial recognition or an approximation thereof where the effect of discounting is material.



3 Changes in accounting policies (Continued)

(B) HKFRS 9, FINANCIAL INSTRUMENTS (Continued)

(ii) Credit losses (Continued)

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

In measuring ECLs, the Group takes into account reasonable and supportable information that is available without undue cost or effort. This includes information about past events, current conditions and forecasts of future economic conditions.

ECLs are measured on either of the following bases:

- 12-month ECLs: these are losses that are expected to result from possible default events within the 12 months after the reporting date; and
- lifetime ECLs: these are losses that are expected to result from all possible default events over the expected lives of the items to which the ECL model applies.

Loss allowances for trade receivables are always measured at an amount equal to lifetime ECLs. ECLs on these financial assets are estimated using a provision matrix based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors and an assessment of both the current and forecast general economic conditions at the reporting date.

Significant increases in credit risk

In assessing whether the credit risk of a financial instrument has increased significantly since initial recognition, the Group compares the risk of default occurring on the financial instrument assessed at the reporting date with that assessed at the date of initial recognition. The Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly since initial recognition:

- failure to make payments of principal or interest on their contractually due dates;
- an actual or expected significant deterioration in a financial instrument's external or internal credit rating (if available);
- an actual or expected significant deterioration in the operating results of the debtor; and
- existing or forecast changes in the technological, market, economic or legal environment that have a significant adverse effect on the debtor's ability to meet its obligation to the Group.

3 Changes in accounting policies (Continued)

(B) HKFRS 9, FINANCIAL INSTRUMENTS (Continued)

(ii) Credit losses (Continued)

Depending on the nature of the financial instruments, the assessment of a significant increase in credit risk is performed on either an individual basis or a collective basis. When the assessment is performed on a collective basis, the financial instruments are grouped based on shared credit risk characteristics, such as past due status and credit risk ratings.

ECLs are remeasured at each reporting date to reflect changes in the financial instrument's credit risk since initial recognition. Any change in the ECL amount is recognised as an impairment gain or loss in profit or loss. The Group recognises an impairment gain or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account.

Basis of calculation of interest income on credit-impaired financial assets

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit-impaired, in which case interest income is calculated based on the amortised cost (i.e. the gross carrying amount less loss allowance) of the financial asset.

At each reporting date, the Group assesses whether a financial asset is credit-impaired. A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable events:

- significant financial difficulties of the debtor;
- a breach of contract, such as a default or delinquency in interest or principal payments;
- it becoming probable that the borrower will enter into bankruptcy or other financial reorganisation; or
- significant changes in the technological, market, economic or legal environment that have an adverse effect on the debtor.

Write-off policy

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off.

Subsequent recoveries of an asset that was previously written off are recognised as a reversal of impairment in profit or loss in the period in which the recovery occurs.

Opening balance adjustment

There has been no impact on the Group as a result of this change in accounting policy.

(iii) Transition

Changes in accounting policies resulting from the adoption of HKFRS 9 have been applied retrospectively, except as described below:

- Information relating to comparative periods has not been restated. Accordingly, the information presented for the year ended
 31 March 2018 continues to be reported under HKAS 39 and thus may not be comparable with the current period.
- The following assessments have been made on the basis of the facts and circumstances that existed at 1 April 2018 (the date of initial application of HKFRS 9 by the Group):
 - the determination of the business model within which a financial asset is held; and
 - the designation of investments in equity instruments not held for trading to be classified as at FVOCI.



3 Changes in accounting policies (Continued)

(C) HKFRS 15, REVENUE FROM CONTRACTS WITH CUSTOMERS

HKFRS 15 establishes a comprehensive framework for recognising revenue and some costs from contracts with customers. HKFRS 15 replaces HKAS 18, *Revenue*, which covered revenue arising from sale of goods and rendering of services, and HKAS 11, *Construction contracts*, which specified the accounting for construction contracts.

The Group has elected to use the cumulative effect transition method and has recognised the cumulative effect of initial application as an adjustment to the opening balance of equity at 1 April 2018. Therefore, comparative information has not been restated and continues to be reported under HKAS 18. As allowed by HKFRS 15, the Group has applied the new requirements only to contracts that were not completed before 1 April 2018.

Further details of the nature and effect of the changes on previous accounting policies are set out below:

(i) Timing of revenue recognition

Previously, revenue from sale of goods was generally recognised at a point in time when the risks and rewards of ownership of the goods had passed to the customers. Under HKFRS 15, revenue is recognised when the customer obtains control of the promised good or service in the contract.

The adoption of HKFRS 15 does not have a significant impact on when the Group recognises revenue from sales of goods.

(ii) Significant financing component

HKFRS 15 requires an entity to adjust the transaction price for the time value of money when a contract contains a significant financing component, regardless of whether the payments from customers are received significantly in advance of revenue recognition or significantly deferred.

There has been no impact on the Group as a result of this change in accounting policy.

(iii) Presentation of contract assets and liabilities

Under HKFRS 15, a receivable is recognised only if the Group has an unconditional right to consideration. If the Group recognises the related revenue before being unconditionally entitled to the consideration for the promised goods in the contract, then the entitlement to consideration is classified as a contract asset.

Similarly, a contract liability, rather than a payable, is recognised when a customer pays consideration, or is contractually required to pay consideration and the amount is already due, before the Group recognises the related revenue. For a single contract with the customer, either a net contract asset or a net contract liability is presented. For multiple contracts, contract assets and contract liabilities of unrelated contracts are not presented on a net basis.

There has been no impact on the Group as a result of this change in accounting policy.

(D) HK(IFRIC) 22, FOREIGN CURRENCY TRANSACTIONS AND ADVANCE CONSIDERATION

This interpretation provides guidance on determining "the date of the transaction" for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income (or part of it) arising from a transaction in which an entity receives or pays advance consideration in a foreign currency.

The Interpretation clarifies that "the date of the transaction" is the date on initial recognition of the non-monetary asset or liability arising from the payment or receipt of advance consideration. If there are multiple payments or receipts in advance of recognising the related item, the date of the transaction for each payment or receipt should be determined in this way. The adoption of HK(IFRIC) 22 does not have any material impact on the financial position and the financial result of the Group.

4 Revenue and segment reporting

(A) REVENUE

The principal activities of the Group are manufacturing and trading of generic drugs and proprietary medicines.

Revenue represents the sales value of goods supplied to customers less returns and sales rebates and is after deduction of any trade discounts.

(B) SEGMENT REPORTING

The Group manages its businesses by divisions, which are organised by business lines. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has presented the following three reportable segments. No operating segments have been aggregated to form the following reportable segments:

- Generic drugs: this segment develops, manufactures and distributes a host of off-patent medicine for various therapeutic use.
 Currently the activities in this regard are primarily carried out in Hong Kong.
- Proprietary medicines: this segment develops, manufactures and distributes medicines. Currently the activities in this regard are
 primarily carried out in Hong Kong.
- Wholesale and retail: this segment sells western and proprietary medicines in Hong Kong.

Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and the expenses incurred by those segments or which otherwise arise from the depreciation or amortisation of assets attributable to those segments.

The measure used for reporting segment profit is "adjusted EBITDA" i.e. "adjusted earnings before interest, taxes, depreciation and amortisation", where "interest" is regarded as including interest income and interest expenses and "depreciation and amortisation" is regarded as including impairment losses on non-current assets. To arrive at adjusted EBITDA the Group's earnings are further adjusted for non-recurring items not attributable to the operations of individual segments.

Inter-segment sales are priced with reference to prices charged to external parties for similar orders.

Segment assets and liabilities of the Group are not reported to the Group's chief operating decision makers regularly. As a result, reportable assets and liabilities have not been presented in the interim financial report.



4 Revenue and segment reporting (Continued)

(B) SEGMENT REPORTING (Continued)

(i) Segment revenue and results

Information regarding the Group's reportable segments as provided to the Group's chief operating decision makers for the purposes of resource allocation and assessment of segment performance for the period is set out below.

	Generio	: drugs	Proprietary	medicines	Wholesale	and retail	То	tal
	Six months ended 30 September				Six months ended 30 September		Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000	2018 HK\$'000	2017 HK\$'000	2018 HK\$'000	2017 HK\$'000	2018 HK\$'000	2017 HK\$'000
Revenue from external customers Inter-segment revenue	595,227 2,171	542,225 1,639	110,743 920	121,183 2,344	110,290 -	79,624	816,260 3,091	743,032 3,983
	597,398	543,864	111,663	123,527	110,290	79,624	819,351	747,015
Reportable segment profit (adjusted EBITDA)	164,700	125,780	43,031	39,794	4,344	2,189	212,075	167,763

(ii) Reconciliations of reportable segment revenue and profit or loss

	Six months ended 30 S	eptember
	2018	2017
	HK\$'000	HK\$'000
Revenue		
Reportable segment revenue	819,351	747,015
Elimination of inter-segment revenue	(3,091)	(3,983)
Consolidated revenue	816,260	743,032
Profit		
Reportable segment profit	212,075	167,763
Elimination of inter-segment profit	(559)	(1,520)
Reportable segment profit derived from Group's external customers	211,516	166,243
Interest income from bank deposits	1,265	31
Fair value gain on investment properties	4,374	2,599
Fair value gain on contingent consideration receivable	-	237
Depreciation and amortisation	(58,511)	(56,406)
Finance costs	(33,252)	(13,874)
Share of profits of associates	1,819	-
Consolidated profit before taxation	127,211	98,830

4 Revenue and segment reporting (Continued)

(B) SEGMENT REPORTING (Continued)

(iii) Geographic information

The following table sets out information about the geographical location of the Group's revenue from external customers. The geographical location of customers is based on the location at which the goods are distributed to the ultimate customers by the Group, the consignees or the distributors.

	Six months ended 30 S	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000	
Revenue from external customers			
Hong Kong (place of domicile)	769,429	696,832	
Mainland China	19,578	18,927	
Масаи	11,961	16,654	
Singapore	5,357	3,384	
Others	9,935	7,235	
	816,260	743,032	

The following table sets out information about the geographical location of the Group's property, plant and equipment, leasehold land, investment properties, intangible assets, prepayment for purchase of non-current assets and interest in associates ("specified non-current assets"). The geographical location of the specified non-current assets is based on the physical location of the asset, in the case of property, plant and equipment and leasehold land, investment properties and the location of the operation to which they are allocated, in the case of intangible assets and non-current prepayments, and the location operations, in the case of interest in associates.

	As at	As at
	30 September	31 March
	2018	2018
	HK\$'000	HK\$'000
Specified non-current assets		
Hong Kong (place of domicile)	2,448,459	2,202,348
Mainland China	43,740	29,676
Масаи	104	122
Cambodia	14,617	14,617
	2,506,920	2,246,763

(iv) Information about major customers

For the six months ended 30 September 2018, the Group's customer base includes one customer of the generic drugs segment with whom transactions have exceeded 10% of the Group's revenue. Revenue from sales of generic drugs to this customer, including sales to entities which are known to the Group to be under common control amounted to HK\$200,100,000 (six months ended 30 September 2017: HK\$184,158,000).



5 Other net income

	Six months ended 30 S	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000	
Commission income	555	336	
Interest income from bank deposits	1,265	31	
Net foreign exchange (loss)/gain	(1,241)	99	
Net loss on disposal of property, plant and equipment	(183)	(110)	
Fair value gain on investment properties	4,374	2,599	
Fair value gain on contingent consideration receivable (note 11)	-	237	
Others	710	510	
	5,480	3,702	

6 Profit before taxation

Profit before taxation is arrived at after charging:

	Six months ended 30	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$`000	
(A) FINANCE COSTS			
Interest on bank loans and other borrowings	33,229	13,855	
Finance charges on obligations under finance leases	23	19	
	33,252	13,874	

	Six months ended 30 S	Six months ended 30 September		
	2018 HK\$'000	2017 HK\$'000		
(B) OTHER ITEMS				
Amortisation				
– leasehold land	725	818		
– intangible assets	13,782	12,826		
Depreciation (note 10)	44,004	42,762		
Write-down of inventories	10,768	8,011		
Research and development costs (other than amortisation of				
capitalised development costs)	3,410	4,234		
Equity settled share-based transactions	3,812	3,500		

7 Income tax

	Six months ende	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000	
Current tax	23,908	17,265	
Deferred taxation	(73)	(1,503)	
	23,835	15,762	

The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% (six months ended 30 September 2017: 16.5%) to the six months ended 30 September 2018. Taxation for overseas subsidiaries is similarly calculated using the estimated annual effective rates of taxation that are expected to be applicable in the relevant countries.

8 Earnings per share

(A) BASIC EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit attributable to shareholders of the Company of HK\$97,531,000 (six months ended 30 September 2017: HK\$80,329,000) and the weighted average of 1,846,226,000 ordinary shares (six months ended 30 September 2017: 1,815,625,000 shares) in issue during the reporting period, calculated as follows:

	Six months ended 30 September	
	2018	2017
	'000	'000
Shares of the Company issued at the beginning of the period	1,815,625	1,815,625
Effect of shares issued during the reporting period (note 14(A))	30,601	-
Weighted average number of ordinary shares in issue during the reporting period	1,846,226	1,815,625

(B) DILUTED EARNINGS PER SHARE

Diluted earnings per share equals to basic earnings per share for the six months ended 30 September 2018 and 2017 because the potential ordinary shares outstanding were anti-dilutive.



9 Dividends

(A) DIVIDENDS PAYABLE TO SHAREHOLDERS ATTRIBUTABLE TO THE REPORTING PERIOD

	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000
Interim dividend declared and paid after the reporting period of HK1.5 cents		
per share (six months ended 30 September 2017: HK0.9 cent per share)	30,234	16,341

The interim dividend has not been recognised as a liability at the end of the reporting period.

(B) DIVIDENDS PAYABLE TO SHAREHOLDERS ATTRIBUTABLE TO THE PREVIOUS FINANCIAL YEAR, APPROVED AND PAID DURING THE REPORTING PERIOD

	Six months ende	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000	
Final dividend in respect of the previous financial year, approved and paid during the following interim period, of HK2.9 cents per share (six months ended 30 September 2017:			
HK1.4 cents per share)	58,453	25,419	

10 Property, plant and equipment and investment properties

(A) PROPERTY, PLANT AND EQUIPMENT

	As at 30 September 2018 HK\$'000	As at 31 March 2018 HK\$'000
Cost:		
At 1 April 2018/2017 Additions Acquisition of subsidiaries	1,293,674 11,284 –	1,277,202 60,042 22
Disposals Transfer from investment properties Exchange difference	(4,502) 62,000 (9,965)	(52,346) - 8,754
At 30 September 2018/31 March 2018	1,352,491	1,293,674
Accumulated depreciation:		
At April 2018/2017 Charge for the period/year Written back on disposals Exchange difference	311,404 44,004 (3,763) (7,589)	269,530 85,072 (50,198) 7,000
At 30 September 2018/31 March 2018	344,056	311,404
Net book value:		
At 30 September 2018/31 March 2018	1,008,435	982,270

(B) INVESTMENT PROPERTIES

During the six months ended 30 September 2018, the Group acquired investment properties at a cost of HK\$128,026,000 (six months ended 30 September 2017: HK\$53,401,000). Investment properties of HK\$62,000,000 were also transferred to property, plant and equipment following a change in use to self occupation during the period.

The valuations of investment properties at fair value as at 30 September 2018 were performed by the Group's independent valuer using the market comparison method. As a result of the valuation, a net gain of HK\$4,374,000 (six months ended 30 September 2017: HK\$2,599,000) has been recognised in profit or loss for the period.

11 Trade and other receivables

As at the end of the reporting period, the ageing analysis of trade receivables (which are included in trade and other receivables) based on the invoice date and net of allowance for doubtful debts, is as follows:

	As at 30 September 2018 HK\$'000	As at 31 March 2018 HK\$'000
Less than 1 month	129,942	113,372
1 to 6 months	66,966	74,955
Over 6 months	7,891	9,083
Trade receivables	204,799	197,410
Other receivables	4,454	5,661
Contingent consideration receivable*	4,647	3,846
Deposits and prepayments	46,128	47,880
	260,028	254,797

* Pursuant to the agreement in connection with the acquisition of 70% equity interest in Hong Ning Hong Limited in April 2017, the seller guaranteed to the Group that the 2018 audited net profit after tax ("Net Profit") and 2019 Net Profit ("Annual Guaranteed Profit") shall each be no less than HK\$8,000,000. In the event that any of the 2018 Net Profit and 2019 Net Profit is less than the Annual Guaranteed Profit, the seller shall pay the shortfall amount to the Group on a dollar to dollar basis and the maximum aggregate shortfall amount which may be paid by the seller shall be capped at HK\$5,000,000. As at 30 September 2018, the fair value of contingent consideration receivable amounted to HK\$4,647,000 (31 March 2018: HK\$4,647,000).

12 Cash and cash equivalents

	As at	As at
	30 September	31 March
	2018	2018
	HK\$'000	HK\$'000
Short-term deposits with banks	156,460	320,601
Cash at bank and in hand	634,942	336,132
	791,402	656,733

13 Trade and other payables

As at the end of reporting period, the ageing analysis of trade payables (which are included in trade and other payables), based on the invoice date, is as follows:

	As at 30 September 2018 HK\$'000	As at 31 March 2018 HK\$'000
Less than 1 month	19,489	18,784
1 to 6 months	12,598	16,404
Trade payables	32,087	35,188
Salary and bonus payables	45,069	37,155
Payables and accruals for additions of property, plant and equipment	1,797	2,373
Other payables and accruals	28,985	28,709
Receipts in advance	4,687	2,128
	112,625	105,553



14 Capital and reserves

(A) SHARE CAPITAL

	Number of shares	Amount HK\$'000
Issued ordinary shares of HK\$0.01 each:		
At 1 April 2017, 31 March 2018 and 1 April 2018 Issue of ordinary shares	1,815,625 200,000	18,156 2,000
At 30 September 2018	2,015,625	20,156

On 14 August 2018, the Company entered into a subscription agreement with Yunnan Baiyao Holdings Company Limited[#] [雲南白藥控股 有限公司] ("Yunnan Baiyao") in respect of 200,000,000 new ordinary shares at the subscription price of HK\$2.06 per share. The Company completed the issuance of the ordinary shares to Yunnan Baiyao on 3 September 2018. Net proceeds from such issue amounted to HK\$411,658,000 (after the deduction of share issuance costs of HK\$342,000) of which HK\$2,000,000 and HK\$409,658,000 were recorded in share capital and share premium respectively.

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All ordinary shares rank equally with regard to the Company's residual assets.

(B) EQUITY SETTLED SHARE-BASED TRANSACTIONS

On 19 April 2017, pursuant to the Share Incentive Scheme adopted by the Company on 30 August 2016, an executive director of the Company was granted share awards entitling him to acquire an aggregate of 6,000,000 ordinary shares of the Company from the trustee of the Share Incentive Scheme and vested on 21 April 2017. All the share awards granted were vested during the six months ended 30 September 2017 and there was no outstanding share awards granted as at 30 September 2017 and 2018.

On 30 June 2017, 36,000,000 share options were granted at a consideration of HK\$1 to certain employees, including certain executive directors of the Company and certain directors of subsidiaries of the Company, under the Company's employee share option scheme. Each option gives the holder the right to subscribe for one ordinary share of the Company. These share options are valid and exercisable within a validity period from 1 October 2017, 2018 and 2019 up to 30 September 2018, 2019 and 2020 respectively in three tranches. The exercise price is HK\$2.06 per share, being the closing price of the shares of the Company as stated in The Stock Exchange of Hong Kong Limited's daily quotations sheets on the date of grant. 500,000 options were lapsed and no options were exercised during the six months ended 30 September 2018 (six months ended 30 September 2017: Nil).

On 18 October 2017, 1,000,000 share options granted at a consideration of HK\$1 to one employee, under the Company's employee share option scheme. Each option gives the holder the right to subscribe for one ordinary share of the Company. These share options are valid for three years commencing from 18 October 2017 up to 17 October 2020 and are exercisable subject to the vesting date on 1 April 2018. The exercise price is HK\$2.13 per share, being the average of the closing prices of the shares of the Company as stated in The Stock Exchange of Hong Kong Limited's daily quotations sheets for the five business days immediately preceding the date of grant. No options were exercised during the six months ended 30 September 2018.

English name for identification purpose only

15 Fair value measurement of financial instruments

(A) FAIR VALUE HIERARCHY

HKFRS 13, *Fair value measurement* categorises fair value measurements into a three-level hierarchy. The level into which fair value is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available
- Level 3 valuations: Fair value measured using significant unobservable inputs

The following table presents the Group's financial assets that were measured at fair value at 30 September 2018.

	Fair value at 30 September 2018 HK\$'000		lue measurements	d into
		Level 1 HK\$'000	ber 2018 categorise Level 2 HK\$'000	Level 3 HK\$'000
Financial assets:				
Financial assets at FVOCI	218,419	-	218,419	-
Contingent consideration receivable (note 11)	4,647	-	-	4,647
	223,066	-	218,419	4,647
	Fair value	Fair va	lue measurements	
	at 31 March	at 31 March 2018 categorised into		nto
	2018	Level 1	Level 2	Level 3
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Financial assets:				
Contingent consideration receivable (note 11)	4,647	-	-	4,647

During the period, there were no transfers between Level 1 and Level 2, or transfers into or out of Level 3. The Group's policy is to recognise transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

(B) VALUATION TECHNIQUES AND INPUTS USED IN LEVEL 2 FAIR VALUE MEASUREMENT

The fair values of the financial assets at FVOCI are determined with reference to the pricing of the recent transactions or offerings of the investees' shares.

(C) VALUATION TECHNIQUES AND INPUTS USED IN LEVEL 3 FAIR VALUE MEASUREMENT

The fair value of the contingent consideration receivable is determined using monte carlo simulation and the significant unobservable input used in the fair value measurement is expected Net Profit. The fair value will increase when the expected Net Profit decreases. As at 30 September 2018, it is estimated that with all other variables held consent, an increase/decrease in the Net Profit by 10% would have decreased/increased the Group's profit by HK\$173,000 (31 March 2018: HK\$55,000).



16 Capital commitments

Capital commitments outstanding at the end of each reporting period not provided for in the interim financial report were as follows:

	As at	As at
	30 September	31 March
	2018	2018
	HK\$'000	HK\$'000
Authorised and contracted for		
 Purchase of non-current assets 	284,004	7,429
 Investment in an associate 	32,779	32,779
	316,783	40,208

17 Material related party transactions

(A) KEY MANAGEMENT PERSONNEL EMOLUMENTS

Emoluments for key management personnel of the Group, who are also Directors of the Company, are as follows:

	Six months ended 30 September	
	2018 HK\$'000	2017 HK\$'000
Short-term employee benefits	4,135	4,969
Post-employment benefits	169	169
Equity compensation benefits	1,925	1,763
	6,229	6,901

18 Non-adjusting events after the reporting period

On 23 August 2018, the Group has entered into an agreement with Dickson Concepts Limited, to acquire 100% equity interest in Dickson Warehousing Limited at a base consideration of HK\$250 million, which is subject to adjustment according to the agreement. This acquisition was subsequently completed on 14 November 2018 and Melborn Property Limited (formerly known as Dickson Warehousing Limited) became a wholly-owned subsidiary of the Group.

Glossary

In this report, unless otherwise specified, the following glossary applies:

"2018 Interim Report"	the interim report of the Company for the six months ended 30 September 2018
"adjusted EBITDA"	earnings before interest, taxes, depreciation and amortisation, where "interest" is regarded as including interest income and interest expenses and "depreciation and amortisation" is regarded as including impairment losses on non-current assets, further adjusted for non-recurring items not attributable to the operations of individual segments
"adjusted EBITDA margin"	adjusted EBITDA divided by revenue and multiplied by 100%
"adjusted profit attributable to shareholders"	profit attributable to the Shareholders excluding one-off listing expense
"ASEAN"	The Association of Southeast Asian Nations
"Board"	Board of Directors
"CG Code"	Corporate Governance Code as amended from time to time contained in Appendix 14 to the Listing Rules
"China" or "the PRC"	the People's Republic of China excluding, for the purpose of this interim report, Hong Kong, Macau Special Administrative Region and Taiwan
"Company" or "our Company" or "the Company"	Jacobson Pharma Corporation Limited, an exempted company incorporated in the Cayman Islands with limited liability on 16 February 2016
"Controlling Shareholders"	Mr. Sum, Mr. Lau, Kingshill, Kingshill Development Group Inc and Longjin
"Deed of Acting in Concert"	the deed of acting in concert dated 8 January 2016 entered into between Kingshill, Longjin and Mr. Lau whereby they confirmed the existence of their acting in concert arrangement
"Dignari"	Dignari Capital Partners GP Limited, the general partner of DCP China Credit Fund I, L.P. to which Dragons 615 Limited was its wholly-owned limited liability company
"Director(s)"	the director(s) of the Company
"FY2018 Interim"	the six months ended 30 September 2017
"FY2019"	the year ended 31 March 2019
"FY2019 Interim" or "reporting period"	the six months ended 30 September 2018
"GMP"	Good Manufacturing Practice, a set of detailed guidelines on practices governing the production of pharmaceutical products designed to protect consumers by minimising production errors and the possibility of contamination
"Group"	the Company and its subsidiaries
"НК\$"	Hong Kong dollars, the lawful currency of Hong Kong
"HKIB"	Hong Kong Institute of Biotechnology
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong Branch Share Registrar"	Tricor Investor Services Limited
"Jacobson", "the Group", "our Group", "we", "us", or "our"	the Company and its subsidiaries
"Kingshill"	Kingshill Development Limited, a limited liability company incorporated under the laws of BVI on



8 July 1998, and one of our Controlling Shareholders

"Listing"	the listing of the Shares on the Main Board
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
"Main Board"	Main Board of the Stock Exchange
"Model Code"	Model Code for Securities Transaction by Directors of Listed Issuers as set out in Appendix 10 of the Listing Rules
"Mr. Lau"	Mr. Lau Wing Hung, one of our Controlling Shareholders
"Mr. Sum"	Mr. Sum Kwong Yip, Derek, our chairman, executive Director, chief executive officer and one of our Controlling Shareholders
"NAMI"	Nano & Advanced Materials Institute Limited
"net debts"	bank loans less cash and cash equivalents
"net gearing ratio"	net debts divided by total equity multiplied by 100%
"PIC/S"	two international instruments, the Pharmaceutical Inspection Convention and the Pharmaceutical Inspection Co-operation Scheme, which seek to promote constructive co-operation in the field of GMP between the participating authorities in different geographic markets
"PIC/S GMP"	Good Manufacturing Practice in accordance with the PIC/S GMP Guide issued by PIC/S
"private sector"	refers to non-public sector
"public sector"	refers to all public institutions and a number of public institutions and clinics in Hong Kong
"Queenshill"	Queenshill Development Limited, a limited liability company incorporated under the laws of BVI on 12 December 2012
"R&D"	research and development
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
"Share(s)"	ordinary share(s) in the capital of the Company with nominal value of HK\$0.01 each
"Shareholder(s)"	holder(s) of Shares
"Share Incentive Scheme"	the share incentive scheme conditionally adopted by our Company on 30 August 2016, the principal terms of which are summarised in "Statutory and General Information – D. Other Information – 2. Share Incentive Scheme" in Appendix V to the Prospectus
"Share Option Scheme"	the share option scheme conditionally adopted by our Company on 30 August 2016, the principal terms of which are summarised in "Statutory and General Information – D. Other Information – 1. Share Option Scheme" in Appendix V to the Prospectus
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"The Kingshill Trust"	The Kingshill Trust is a discretionary trust established by Mr. Sum (as settlor) on 16 May 2016 with Mr. Sum and his family members as the discretionary beneficiaries
"The Queenshill Trust"	The Queenshill Trust is a discretionary trust established by Mr. Sum (as settlor) on 16 May 2016 with Mr. Sum and his family members as the discretionary beneficiaries

* English name for identification purpose only